Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: Lessons from an observational cohort study.

December 22, 2015 at 8:31 am

Infection 2015 Oct 15

Dina Creemers-Schild, Frank P. Kroon, Ed. J. Kuijper, Mark G. J. de Boer

Department of Infectious Diseases, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands

Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

Background

The recommended treatment of Pneumocystis jirovecii pneumonia (PCP) is high-dose trimethoprim–sulfamethoxazole (TMP–SMX) in an equivalent of TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day for 2 or 3 weeks. High rates of adverse events are reported with this dose, which raises the question if lower doses are possible.

Methods

All adult patients diagnosed with PCP in various immune dysfunctions and treated with TMP–SMX between January 1, 2003 and July 1, 2013 in a tertiary university hospital were included. Per institutional protocol, patients initiated treatment on intermediate-dose TMP–SMX (TMP 10–15 mg/kg/day) and could be stepped down to low-dose TMP–SMX (TMP 4–6 mg/kg/day) during treatment. Clinical variables at presentation, relapse rate and mortality rates were compared between intermediate- and step-down treatment groups by uni- and multivariate analyses.

Results

A total of 104 patients were included. Twenty-four patients (23 %) were switched to low-dose TMP–SMX after a median of 4.5 days (IQR 2.8–7.0 days). One relapse (4 %) occurred in the step-down group versus none in the intermediate-dose group. The overall 30-day mortality was 13 %. There was 1 death in the step-down group (4 %) compared to 13 deaths (16 %) in the intermediate-dose group.

Conclusions

We observed high cure rates of PCP by treatment with intermediate-dose TMP–SMX. In addition, a step-down strategy to low-dose TMP–SMX during treatment in selected patients appears to be safe and does not compromise the outcome of treatment.

abstract

http://link.springer.com/article/10.1007%2Fs15010-015-0851-1

PDF

http://download.springer.com/static/pdf/174/art%253A10.1007%252Fs15010-015-0851-1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs15010-015-0851-1&token2=exp=1450784605~acl=%2Fstatic%2Fpdf%2F174%2Fart%25253A10.1007%25252Fs15010-015-0851-1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs15010-015-0851-1*~hmac=631be9d6e6d51a6cab7261bbad2f902231fc812d7b9685ea6777ac3747563a2c

Entry filed under: Antimicrobianos, Bacterias, Epidemiología, HIV/SIDA, HIV/SIDA Complicaciones, HIV/SIDA Trastornos respiratorias, Infecciones respiratorias, Metodos diagnosticos, REPORTS, Sepsis, Update. Tags: .

Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality Infection Prevention and Evaluation of Fever After Laparoscopic Hysterectomy.


Calendar

December 2015
M T W T F S S
« Nov   Jan »
 123456
78910111213
14151617181920
21222324252627
28293031  

Most Recent Posts


%d bloggers like this: